Melissa Glassford, DNP, discusses clinical strategies for managing GLP-1 therapy gaps, dose titration, weight plateaus, and side effects in obesity.

As cannabis legalization expands nationally, what should your patients with diabetes know about the risks and benefits?

The WHO released a guideline on the use of GLP-1 therapies for the treatment of obesity among adults.

In light of Serena Williams’s endorsement of GLP-1 medications, we interviewed an obesity medicine specialist about the implications of these medications for professional athletes.

Changes in estrogen are often solely attributed to the menopause-CVD connection. How can physicians avoid overfocusing on hormones in menopause?